Kairos Pharma (KAPA) Assets Average (2024 - 2025)
Kairos Pharma's (KAPA) quarterly Assets Average came in at $6.6 million in Q4 2025, up 22.66% YoY from $5.4 million in Q4 2024, and down 9.56% on a QoQ basis from $7.3 million in Q2 2025.
Kairos Pharma (KAPA) Assets Average (2024 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 2 years of Assets Average data on file, last reported at $6.6 million in Q4 2025.
- Quarterly Assets Average rose 22.66% year-over-year to $6.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.6 million (up 22.66% YoY) and the FY2025 annual result came in at $6.2 million, up 82.8% from the prior year.
- Assets Average slipped to $6.6 million in Q4 2025, from $7.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $7.3 million in Q2 2025 to a low of $5.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 19.82 Bn |
| 10 | Kairos Pharma | 5.46 Mn | 124,153.18 | - | 6.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.61 Mn |
| Jun 30, 2025 | 7.31 Mn |
| Mar 31, 2025 | 6.85 Mn |
| Dec 31, 2024 | 5.39 Mn |